Navigation Links
Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
Date:3/11/2009

Unmet Need for Efficacious Therapies for Treating Patients With Mutated KRAS Genes Presents Significant Opportunity for Drug Developers, According to a New Report from Decision Resources

WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches of Roche/Genentech/Chugai's Avastin and Bristol-Myers Squibb/ImClone Systems*/Merck KGaA's Erbitux will drive the colorectal cancer market to grow by $900 million to $7.8 billion in 2017.

The new Pharmacor report entitled Colorectal Cancer finds that market growth will be driven by the launches of Avastin and Erbitux into the adjuvant setting in 2011 in the United States and 2012 in Europe. Additionally, among the emerging therapies that will launch for colorectal cancer over the next several years, AstraZeneca's Recentin, Pfizer's Sutent and Sanofi-Aventis/Regeneron's VEGF Trap will account for 9.2 percent of market sales in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Although monoclonal antibodies such as Avastin and Erbitux and emerging tyrosine kinase inhibitors and vascular endothelial growth factor inhibitors will drive growth, generic erosion will take market share away from some currently-available therapies, including oxaliplatin (Sanofi-Aventis's Eloxatin/Eloxatine and Yakult Honsha's Elplat). The expected entrance of generic oxaliplatin in the U.S. colorectal cancer market in late 2009 and in Japan in 2013 will reduce major-market sales of branded forms of this agent by almost $800 million in 2017.

The report also finds that there is significant remaining unmet need in the market for treating patients with mutated KRAS genes who do not respond to therapy using epidermal growth factor receptor (EGFR) inhibitors.

"In recent years, clinical data have shown that patients with mutated KRAS genes do not respond to treatment with EGFR inhibitors, creating a significant unmet need for efficacious agents in the second-line setting for patients who have progressed on Avastin," said Decision Resources Analyst Marcus Hoyle. "This unmet need, coupled with a rising incidence of colorectal cancer, presents a considerable commercial opportunity for drug developers in this market."

*ImClone Systems is a wholly-owned subsidiary of Eli Lilly and Company.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                Decision Resources, Inc.
    Christopher Comfort               Elizabeth Marshall
    781-296-2597                      781-296-2563
    ccomfort@dresources.com           emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
2. Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017
3. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
4. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
5. Avastin Added to Chemo Helps Women With Advanced Cancer
6. Off-Label Avastin Use for Wet Macular Degeneration
7. FDA OKs Avastin for Advanced Breast Cancer
8. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
9. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
10. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
11. Taxol with avastin produces noteworthy results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded ... to confront and deal with these stressors is to adopt a more healthful diet, ... for you. Risa Groux, a certified Holistic Nutritionist and the creator of the Newport ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is ... even security. Most importantly, employees are the single most important asset in creating ... so unhappy? , Just under half of American workers are emotionally checked out ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... student loans more flexibility in repaying their loans, more information about their loan ... time when total outstanding student loan debt, including federal and private loans, has ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart ... at its new location in the Exchange Furniture Mall at 112 Vilseck Road in ... 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general dentists ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician group ... of their physicians has been invited to be a featured speaker at the Texas ... conference on April 30, 2016. , Dr. R. Scott McPherson, a physical medicine ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  Marking its one year anniversary ... ovarian cancer risk test, Color Genomics ... that highly impact the most common hereditary cancers ... Color Test analyzes hereditary cancer risks for breast, ... cancers. The Color Test is physician ordered and ...
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... WARSAW, Ind., April 28, 2016 , Net ... a reported basis over the prior year period, and an ... basis , Diluted EPS for the first quarter were ... period, and $2.00 adjusted, an increase of 29.9% over the ... revenue and adjusted earnings guidance for 2016 Zimmer ...
Breaking Medicine Technology: